Seven pharma stocks that will be in the spotlight in today’s trade (July 28)

Laurus Labs has informed the exchanges that the Andhra Pradesh government has allotted 531.77 acres of land in IP Rambilli Phase-II of Anakapalli district to the company to establish the Laurus Pharma Zone (LPZ) for pharma products manufacturing units. The company has projected investment of ₹5,630 crore and employment to 6,350 people in three phases over a period of eight years. With this allotment, the company has secured an important component for future expansion of its business i.e. land parcel.

Sun Pharma, Lupin and Dr Reddy’s Laboratories are recalling drugs in the US market due to manufacturing issues and product mix-up, according to the US health regulator. According to the latest Enforcement Report of the US Food and Drug administration, the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules due to “Failed Dissolution Specifications”, the US health regulator stated. Meanwhile, in a separate stock exchange note Dr. Reddy’s Laboratories said it has made an investment of Rs 565.40 crore in Dr. Reddy’s Laboratories LLC, Russia (DRL Russia), a step-down wholly-owned subsidiary, for a total equity stake of 45.19%. 

Genpharmasec has acquired 70% stake in Derren Healthcare pursuant to which the latter has become a subsidiary of the company. Objects of acquisition are to expand the activities of Genpharmasec and to make a foray in manufacture of formulations. The acquisition has been done at a purchase consideration of ₹34.15 crore. 

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tegretol-XR Extended-Release Tablets, 100 mg, 200 mg, and 400 mg, of Novartis Pharmaceuticals Corporation. Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug and also for the treatment of pain associated with true trigeminal neuralgia. Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg, and 400 mg, have an estimated market size of $71 million for twelve months ending March 2025 according to IQVIA. Alembic has a cumulative total of 225 ANDA approvals (202 final approvals and 23 tentative approvals) from USFDA. 

The Delhi High Court has said that it cannot issue direction to Zydus Lifesciences to disclose its manufacturing process for breast cancer drug Sigrima, as petitioner Swiss multinational firm F. Hoffmann-La Roche failed to fulfil the mandatory requirements to invoke the relevant provisions under the Patents Act, 1970, for the same. The latest order is in connection with a dispute raised by Roche against Zydus, alleging that the latter’s drug Sigrima infringes its patent rights for monoclonal antibody (MAb) biologic drug Pertuzumab, branded as Perjeta. The Court has been considering enabling confidentiality club and permitting its members to access the process used by Zydus Lifesciences for manufacturing its product Sigrima, invoking the Section 104A of the Patent Act. Zydus had earlier submitted the details of the manufacturing process as sealed, with the Court in March, 2024.

Published on July 28, 2025